An Open-Label, Uncontrolled Clinical Trial of Oral 566C80 for the Treatment of Patients With Severe PCP Who Are Intolerant and/or Unresponsive to Therapy With Trimethoprim/Sulfamethoxazole and Parenteral Pentamidine

Conditions

• Pneumonia, Pneumocystis Carinii
• HIV Infections

Interventions

• DRUG: Atovaquone

Sponsor

Glaxo Wellcome